Beroni Group, a biopharmaceutical developer focused on treating of global diseases, will leverage its nanobody technology for the novel coronavirus (COVID-19) in collaboration with Tianjin University in China to advance into cytological experiments in March 2020. The research team has been able to obtain information on the coronavirus nanobody sequence and the complex crystal structure of SARS-CoV-2, the virus causing the infection. After evaluating the effect of the antibody modification, th...